Portico Next Generation Approval Study
NCT: NCT04011722 · ACTIVE_NOT_RECRUITING
Brief Summary
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.
Frequently Asked Questions
What is Portico Next Generation Approval Study?
Portico Next Generation Approval Study is a clinical trial registered under NCT04011722. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT04011722?
The current status of NCT04011722 (Portico Next Generation Approval Study) is: ACTIVE_NOT_RECRUITING.
When did Portico Next Generation Approval Study start?
Portico Next Generation Approval Study started on 2019-09-17.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.